Investor Presentation

02.11.2026 National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, Floor- 25, P J Tower, Bandra-Kurla Complex, Dalal Street, Bandra (East) Mumbai 400 051 Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation on Un-Audited Financial Results – Q2 FY27 Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Investors Presentation on Un-Audited Financial Results – Q2 FY27. The said Earnings Presentation is also available at www.epigral.com in the Investor Relations section. This is for information and records. Thanking you, Yours faithfully, For Epigral Limited Gaurang Trivedi Company Secretary & Compliance Officer M. No. 22307 Epigral Limited Investor Presentation – Q2FY2027 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Epigral Limited (the “Company”) solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company Certain statements in this presentation concerning our future growth prospects are forward looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Risk and uncertainties relating to the statements include, but are not limited to, risks and uncertainties regarding fiscal policy, competition, inflationary pressures and general economic conditions affecting demand / supply and price conditions in domestic and international markets. The company does not undertake to update any forward -looking statement that may be made from time to time by or on behalf of the company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The Company does not make any promise to update/provide such presentation along with results to be declared in the coming years. Q2FY27 Result update Key Highlights Q2FY27 Key Financial Highlights: o YoY sales volume grew by 6%, despite the challenging and volatile market conditions o Revenue grew by 28% to ₹ 752 Crore on account of volume growth and majorly due to improved realizations o Derivatives & Specialty business contributed 57% of revenue vs 50% in Q2FY26 o EBITDA grew by 3% to ₹ 136 Crore vs ₹ 132 Crore. EBITDA margin was muted on account of high cost of raw materials and stood at 18% o PAT grew by 26% to ₹ 64 Crore vs ₹ 51 Crore. H1FY27 Key Financial Highlights: o Revenue increased by 21% to ₹1,461 Crore, compared to ₹1,204 Crore, even after geopolitical tensions, volatile price movements, and off season for few of our products o EBITDA grew by 7% to ₹ 315 Crore vs ₹ 296 Crore. EBITDA margin was maintained at 22% o PAT rose by 25% to ₹ 164 Crore vs ₹ 131 Crore. PAT margin stood at 11% o Net Debt/EBITDA stood at 0.9x as on 30th September 2026 vs 0.8x as on 30th September 2025 Key Highlights H1FY27 Strategic Highlights: o Epigral spent ₹ 88 Crore on capex in H1FY2027 o Epigral’s board approved capex in below two projects, which are expected to commission by H2FY28 • Epoxy Resin & Formulations plant with capacity of 1,25,000 TPA • Multi-Purpose Plant (MPP) downstream for Epichlorohydrin (ECH) and Chlorotoluene Value Chain o Epigral has set up pilot plant for Epoxy Resin & Formulations and MPP to optimise manufacturing process, validate product quality and facilitate customer approvals ahead of commercial scale production o Capex of enhancing CPVC Resin, ECH and Wind Solar Hybrid Power Plant capacity are in last lag of project and should be commissioned in a quarters time CMD Message “Despite a challenging operating environment in Q2FY27, we achieved revenue growth of 28%, driven by volume growth and improved realisations. Elevated raw material prices had its impact on EBITDA margins; however, our H1FY27 performance remained resilient, with revenue growth of 21% and an EBITDA margin of 22%. With the second half of the fiscal traditionally delivering stronger performance than the first, we maintain positive outlook for H2FY27.” “Fueled by India's robust demand growth, we are executing our expansion plans on schedule. The CPVC and ECH expansions are in their final stages with trial runs underway; both plants are expected to commission in a quarter’s time. Meanwhile, our Epoxy Resin & Formulation and MPP projects are progressing as planned. The Revenue contribution from Derivatives & Specialty business stood at 57% and will expand further with these projects”. Epigral remains focused on strengthening its integrated manufacturing ecosystem, broadening its portfolio of high-value chemical products, and creating long-term value for all stakeholders” - Mr. Maulik Patel, Chairman and Managing Director Q2FY27 Financial Highlights EBITDA PAT Revenue 752 25% Q1FY27 Q2FY26 Q2FY27 Q1FY27 Q2FY26 Q2FY27 Q1FY27 Q2FY26 Q2FY27 ₹ Crore Margin -% H1FY27 Financial Highlights EBITDA PAT Revenue 1,461 1,204 22% 11% 11% H1FY26 H1FY27 H1FY26 H1FY27 H1FY26* H1FY27 ₹ Crore Margin -% *As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 212 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 131 Cr Key ratios as on 30th September 2026 ROCE (%)*# ROE (%)* Net Debt/EBITDA (x)* 16% 15% 12% 13% Q1FY27 Q2FY26 Q2FY27 Q1FY27 Q2FY26^ Q2FY27 Q1FY27 Q2FY26 Q2FY27 *TTM EBIT, PAT and EBITDA are considered for above ratios #Capital employed in ROCE includes Capital Work in Progress ^PAT considered here for ROE for Q1FY26 is of Rs. 79 Cr (instead of Rs. 160 Cr), after reducing it by Rs. 81 Cr for benefit of reduction in Deferred tax liability, as the company shifted to new tax rate of 25.17% from FY2026 Revenue Transition towards Derivatives & Specialty Chemicals 52% 51% 50% 50% 48% 49% Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 - Chlor-Alkali - Derivatives & Specialty Chemical Capex Plan Capex Plan: Epoxy Resin and Multi Purpose Plant Epoxy Resin & Formulations Multi Purpose Plant (MPP) Project Details Project Details o Capacity: 1,25,000 TPA o Downstream of Epichlorohydrin and Chlorotoluenes Value Chain o Location: Existing Complex, Dahej o Location: Exiting Complex, Dahej o Expected commissioning: H2FY28 o Expected commissioning: H2FY28 Rationale Rationale o Growing demand in India, expected to grow at double digit percentage o Import substitute products o Strengthening integrated complex: Epichlorohydrin o Strengthening integrated complex: ECH and and Caustic Soda are among the key raw materials Chlorotoluenes Value Chain will be consumed as o Catering to industries such as construction, renewables energy, automotive, electronics, o Catering to Agrochemical and Pharmaceuticals infrastructure, marine, aerospace, industrial flooring, Intermediates and Water Treatment Chemicals o Strengthening Epigral’s position in Specialty Chemicals Capex Plan: Enhancing CPVC and Epichlorohydrin CPVC Epichlorohydrin (ECH) Project Details Project Details o Additional capacity – 75,000 TPA o Additional capacity – 50,000 TPA o Total capacity after expansion – 1,50,000 TPA o Total capacity after expansion – 1,00,000 TPA (World’s largest plant by capacity) (India’s largest plant by capacity) o Expected commissioning – Q3FY27 o Expected commissioning – Q3FY27 Rationale Ra [Showing first 8,000 characters — download PDF for full document]